Department of Radiation Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA.
Department of Radiation Oncology, NYU Grossman School of Medicine, New York University, New York, New York, USA.
J Appl Clin Med Phys. 2022 Mar;23(3):e13522. doi: 10.1002/acm2.13522. Epub 2022 Jan 9.
Detector arrays and profile-scans have widely replaced film-measurements for quality assurance (QA) on linear accelerators. Film is still used for relative output factor (ROF) measurements, positioning, and dose-profile verification for annual Leksell Gamma Knife (LGK) QA. This study shows that small-field active detector measurements can be performed in the easily accessed clinical mode and that they are an effective replacement to time-consuming and exacting film measurements.
Beam profiles and positioning scans for 4-mm, 8-mm, and 16-mm-collimated fields were collected along the x-, y-, and z-axes. The Exradin W2-scintillator and the PTW microdiamond-detector were placed in custom inserts centered in the Elekta solid-water phantom for these scans. GafChromic EBT3-film was irradiated with single uniformly collimated exposures as the clinical-standard reference, using the same solid-water phantom for profile tests and the Elekta film holder for radiation focal point (RFP)/patient-positioning system (PPS) coincidence. All experimental data were compared to the tissue-maximum-ratio-based (TMR10) dose calculation.
The detector-measured beam profiles and film-based profiles showed excellent agreement with TMR10-predicted full-width, half-maximum (FWHM) values. Absolute differences between the measured FWHM and FWHM from the treatment-planning system were on average 0.13 mm, 0.08 mm, and 0.04 mm for film, microdiamond, and scintillator, respectively. The coincidence between the RFP and the PPS was measured to be ≤0.5 mm with microdiamond, ≤0.41 mm with the W2-1 × 1 scintillator, and ≤0.22 mm using the film-technique.
Small-volume field detectors, used in conjunction with a clinically available phantom, an electrometer with data-logging, and treatment plans created in clinical mode offer an efficient and viable alternative for film-based profile tests. Position verification can be accurately performed when CBCT-imaging is available to correct for residual detector-position uncertainty. Scans are easily set up within the treatment-planning-system and, when coupled with an automated analysis, can provide accurate measurements within minutes.
探测器阵列和轮廓扫描已广泛取代胶片测量,用于直线加速器的质量保证(QA)。胶片仍用于相对输出因子(ROF)测量、定位和年度 Leksell Gamma Knife(LGK)QA 的剂量分布验证。本研究表明,小射野有源探测器测量可以在易于访问的临床模式下进行,并且可以有效地替代耗时且严格的胶片测量。
在 X、Y 和 Z 轴上收集了 4-mm、8-mm 和 16-mm 准直野的射束轮廓和定位扫描。在 Elekta 固体水模体中,将 Exradin W2 闪烁体和 PTW 微金刚石探测器放置在定制插件中进行这些扫描。GafChromic EBT3 胶片作为临床标准参考,使用相同的固体水模体进行轮廓测试和 Elekta 胶片架用于辐射焦点(RFP)/患者定位系统(PPS)重合度,用单一均匀准直照射进行单次曝光照射。将所有实验数据与基于组织最大比(TMR10)的剂量计算进行比较。
探测器测量的射束轮廓和胶片基的轮廓与 TMR10 预测的全宽半最大值(FWHM)值非常吻合。测量的 FWHM 与治疗计划系统的 FWHM 之间的绝对差异平均为 0.13mm、0.08mm 和 0.04mm,分别为胶片、微金刚石和闪烁体。使用微金刚石时,RFP 和 PPS 的重合度测量值≤0.5mm,使用 W2-1×1 闪烁体时≤0.41mm,使用胶片技术时≤0.22mm。
在临床可用的模体、具有数据记录功能的静电计和在临床模式下创建的治疗计划的配合下,使用小体积的场探测器可以提供一种高效且可行的胶片基轮廓测试替代方案。当有 CBCT 成像可用时,可以准确地进行位置验证,以纠正残余的探测器位置不确定性。扫描可以在治疗计划系统中轻松设置,并且当与自动分析结合使用时,可以在几分钟内提供准确的测量结果。